Peptinov
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2023-07-01attributed |
| Founded | unknown |
| Headquarters | France |
| Industry | biotech |
| Stage | unknown |
| Website | peptinov.fr |
Peptinov develops peptide-based active immunotherapies that train patients to produce antibodies against their own pathogenic targets. It serves patients with chronic inflammatory diseases and the pharma partners that license its platform assets. The peptide-based active vaccination approach is positioned as a cheaper, longer-acting alternative to monoclonal antibody therapy.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-07-01 | grant | $2.7M | undisclosed |
Detected tech stack
Vue.js 2.6.14, vue 2.6.14
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | peptinov.fr, read 2026-05-07 |
| Description | self-reported | peptinov.fr, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.